HRZE in Pregnancy
For pregnant women with active tuberculosis, the standard HRZE regimen (isoniazid, rifampin, pyrazinamide, and ethambutol) should be used for the full 6-month course (2 months of HRZE followed by 4 months of HR), as untreated TB poses far greater risks to both mother and fetus than the medications.
Treatment Regimen
The recommended approach for active TB in pregnancy is:
- Initial Phase (2 months): Isoniazid + Rifampin + Pyrazinamide + Ethambutol daily
- Continuation Phase (4 months): Isoniazid + Rifampin daily
All four first-line drugs can and should be used during pregnancy 1, 2. The need to treat active TB during pregnancy is unquestioned, as untreated disease endangers both mother and baby 3.
Safety Profile of Individual Drugs
Isoniazid
- Crosses the placenta but is not teratogenic even when given during the first trimester 3
- Extensive safety data in pregnancy 2
- Pyridoxine (vitamin B6) supplementation is mandatory: 25-50 mg/day 1, 4
Rifampin
- Generally safe with extensive experience in pregnant women 3
- One older study showed 3% abnormality rate (vs. 1% for isoniazid controls), but this has not been confirmed in broader clinical experience 3
- Risk of hemorrhagic disease of newborn has been described but is rare 3
- Overall considered safe in most circumstances 3
Pyrazinamide
- WHO recommends pyrazinamide as part of standard treatment in pregnancy 1
- Used extensively in high-burden countries for many years with good safety record 1
- Limited published data on fetal effects, but clinical experience supports safety 3, 2
- Should be included in pregnancy regimens, particularly for severe disease, extrapulmonary TB, or HIV co-infection 1
Ethambutol
- 2% abnormality rate in one study (comparable to controls) 3
- Included in standard pregnancy regimens 2
- Safe for use throughout pregnancy 2
Critical Monitoring Requirements
Pregnant women require enhanced surveillance due to increased risk of isoniazid hepatotoxicity 3, 5:
- Baseline liver function tests (AST/ALT, bilirubin) are mandatory 3, 5
- Monthly clinical evaluation for signs/symptoms of hepatitis 3, 5
- Consider more frequent laboratory monitoring given pregnancy-related hepatotoxicity risk 3
- Educate patient to stop treatment immediately and seek evaluation if symptoms of hepatitis develop 3, 5
Special Considerations
HIV Co-infection
- Same HRZE regimen is effective 6
- Treatment should not be delayed even in first trimester for HIV-positive pregnant women 3, 5
- Be aware of drug interactions between rifampin and antiretroviral therapy 7
Timing of Treatment Initiation
- For high-risk women (HIV-positive, recent infection, severe disease): Do not delay treatment based on pregnancy alone, even during first trimester 3, 5
- For lower-risk women with latent TB (not active disease): some experts recommend waiting until after delivery 3, 5
Breastfeeding
- Breastfeeding is encouraged when mother is non-infectious and on first-line therapy 1
- Small drug concentrations in breast milk do not cause toxicity 3, 1
- Continue pyridoxine supplementation for breastfeeding mothers on isoniazid 3
- Exclusively breastfed infants should receive pyridoxine 1-2 mg/kg/day 1
Common Pitfalls to Avoid
- Do not omit pyrazinamide based on outdated concerns—WHO and international experience support its use 1
- Do not delay treatment in pregnant women with active TB—the disease poses greater risk than the medications 3, 1
- Do not forget pyridoxine supplementation—this is mandatory for all pregnant women on isoniazid 1, 4
- Do not use streptomycin—it causes ototoxicity in approximately 1 in 6 babies 2, 7
- Do not reduce treatment duration—full 6-month course is required 1, 6
Pharmacokinetic Considerations
Recent data show that isoniazid and ethambutol concentrations may be lower during pregnancy (particularly third trimester), while rifampin and pyrazinamide remain adequate 8. However, median drug levels still meet therapeutic targets with standard WHO weight-based dosing 8. Close clinical monitoring for treatment response is warranted, but routine dose increases are not currently recommended.